Your browser is no longer supported. Please, upgrade your browser.
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-7.83 Insider Own4.50% Shs Outstand78.50M Perf Week9.76%
Market Cap14.63B Forward P/E- EPS next Y-5.26 Insider Trans-0.59% Shs Float75.13M Perf Month-46.22%
Income-600.50M PEG- EPS next Q-1.82 Inst Own92.60% Short Float10.53% Perf Quarter-36.98%
Sales495.10M P/S29.56 EPS this Y-77.80% Inst Trans0.20% Short Ratio5.01 Perf Half Y-46.08%
Book/sh11.36 P/B7.95 EPS next Y24.90% ROA-23.00% Target Price- Perf Year-30.68%
Cash/sh11.21 P/C8.06 EPS next 5Y- ROE-61.60% 52W Range78.06 - 181.83 Perf YTD-47.02%
Dividend- P/FCF308.73 EPS past 5Y-23.40% ROI-47.10% 52W High-50.33% Beta1.65
Dividend %- Quick Ratio5.60 Sales past 5Y108.10% Gross Margin88.60% 52W Low15.71% ATR11.08
Employees743 Current Ratio6.10 Sales Q/Q45.40% Oper. Margin- RSI (14)23.10 Volatility7.76% 5.03%
OptionableYes Debt/Eq0.79 EPS Q/Q-47.00% Profit Margin- Rel Volume2.14 Prev Close89.90
ShortableYes LT Debt/Eq0.79 EarningsNov 05 AMC Payout- Avg Volume1.58M Price90.32
Recom1.90 SMA20-40.08% SMA50-38.56% SMA200-37.46% Volume3,382,016 Change0.47%
Jan-12-21Downgrade Citigroup Buy → Neutral $215 → $108
Jan-11-21Downgrade UBS Buy → Neutral
Jan-08-21Downgrade Raymond James Outperform → Mkt Perform
Jan-08-21Downgrade Morgan Stanley Overweight → Equal-Weight $95
Jan-08-21Downgrade JP Morgan Overweight → Underweight $96
Nov-11-20Initiated Berenberg Hold
Oct-28-20Initiated UBS Buy $212
Aug-25-20Initiated Raymond James Outperform $200
Aug-20-20Downgrade Credit Suisse Outperform → Neutral $185 → $167
Mar-31-20Initiated Mizuho Buy $183
Nov-01-19Initiated Guggenheim Buy $183
Aug-21-19Reiterated Needham Buy $196 → $170
Jul-09-19Reiterated Morgan Stanley Overweight $165 → $220
Jul-01-19Reiterated RBC Capital Mkts Outperform $188 → $220
Apr-12-19Initiated Evercore ISI Outperform
Mar-11-19Reiterated Credit Suisse Outperform $189 → $207
Oct-12-18Initiated Bernstein Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Sep-26-18Reiterated RBC Capital Mkts Outperform $187 → $200
Sep-14-18Resumed BofA/Merrill Buy $199
Jan-15-21 01:20PM  
Jan-14-21 12:28PM  
10:26AM  
Jan-13-21 01:00PM  
08:30AM  
Jan-12-21 01:30PM  
10:17AM  
08:57AM  
06:00AM  
Jan-11-21 08:01PM  
03:11PM  
02:45PM  
12:00PM  
08:11AM  
Jan-10-21 01:00PM  
07:56AM  
Jan-09-21 07:15PM  
01:15PM  
Jan-08-21 07:23PM  
06:48PM  
05:16PM  
04:30PM  
01:35PM  
01:25PM  
11:57AM  
11:44AM  
11:38AM  
10:15AM  
09:39AM  
09:36AM  
09:08AM  
08:30AM  
Jan-07-21 05:13PM  
05:11PM  
04:05PM  
Jan-06-21 04:15PM  
Jan-05-21 06:00AM  
Jan-04-21 10:32AM  
Dec-31-20 06:30PM  
Dec-24-20 04:41AM  
Dec-22-20 12:56PM  
Dec-20-20 03:14PM  
Dec-18-20 02:00PM  
Dec-14-20 08:30AM  
Dec-09-20 10:42AM  
Dec-08-20 10:07AM  
Dec-07-20 01:57PM  
08:55AM  
Dec-05-20 11:32AM  
Dec-04-20 04:05PM  
Nov-30-20 06:05PM  
Nov-25-20 08:30AM  
Nov-20-20 08:30AM  
Nov-09-20 09:30AM  
Nov-06-20 02:27PM  
12:01PM  
10:51AM  
Nov-05-20 04:59PM  
04:05PM  
04:02PM  
02:45PM  
Nov-02-20 04:30PM  
Oct-30-20 07:16PM  
Oct-29-20 02:25PM  
12:35PM  
08:36AM  
Oct-23-20 12:56PM  
Oct-22-20 07:30AM  
Oct-01-20 04:43PM  
02:56PM  
Sep-30-20 06:15PM  
Sep-28-20 05:06PM  
08:55AM  
08:55AM  
Sep-16-20 10:29AM  
Sep-15-20 08:30AM  
Sep-14-20 08:30AM  
Sep-10-20 04:32PM  
10:19AM  
07:38AM  
07:20AM  
Sep-09-20 05:19PM  
Sep-08-20 11:58PM  
03:40PM  
Sep-04-20 11:31AM  
Sep-03-20 04:30PM  
Aug-31-20 06:30PM  
Aug-26-20 10:44PM  
11:36AM  
Aug-25-20 04:45PM  
04:45PM  
08:45AM  
Aug-11-20 10:19AM  
08:30AM  
Aug-06-20 10:54AM  
Aug-05-20 06:05PM  
04:05PM  
Jul-31-20 06:15PM  
Jul-29-20 12:33PM  
08:30AM  
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; SRP-9003, a limb-girdle muscular dystrophies gene therapy program; and LYS-SAF 302 to treat mucopolysaccharidosis type IIIA. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; StrideBio; the United States Army Medical Research Institute of Infectious Diseases; the Department of Defense's lead laboratory; the Dyno Therapeutics, Inc; and Personalis, Inc. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bratica JosephPrincipal Financial OfficerDec 11Option Exercise71.451,11579,6679,255Dec 14 08:00 PM
Bratica JosephPrincipal Financial OfficerDec 11Sale165.001,115183,9758,140Dec 14 08:00 PM
GRAY MARY ANNDirectorDec 10Option Exercise0.0096705,710Dec 10 08:24 PM
Bratica JosephPrincipal Financial OfficerDec 08Option Exercise29.601,12533,3009,265Dec 10 08:23 PM
Bratica JosephPrincipal Financial OfficerDec 08Sale160.001,125180,0008,140Dec 10 08:23 PM
Wigzell Hans Lennart RudolfDirectorAug 10Option Exercise34.9210,000349,20023,792Aug 11 08:00 PM
Wigzell Hans Lennart RudolfDirectorAug 10Sale159.0010,0001,590,04413,792Aug 11 08:00 PM
Barry RichardDirectorAug 07Sale158.5030,0004,754,9723,129,140Aug 07 08:00 PM
Bratica JosephPrincipal Financial OfficerAug 03Option Exercise29.601,12533,3008,957Aug 05 08:00 PM
Bratica JosephPrincipal Financial OfficerAug 03Sale155.001,125174,3757,832Aug 05 08:00 PM
Mahatme SandeshEVP, CFO & CBOJul 08Option Exercise19.693,80674,94120,260Jul 09 08:00 PM
Howton David TEVP, General CounselJun 22Option Exercise25.76105,1222,708,440136,993Jun 22 09:17 PM
Howton David TEVP, General CounselJun 22Sale170.88105,12217,962,83131,871Jun 22 09:17 PM
Wigzell Hans Lennart RudolfDirectorMay 20Option Exercise10.085,00050,40018,792May 22 08:00 PM
Wigzell Hans Lennart RudolfDirectorMay 20Sale150.645,000753,21013,792May 22 08:00 PM
Barry RichardDirectorMay 15Sale141.2630,0004,237,9463,159,140May 15 09:02 PM
Wigzell Hans Lennart RudolfDirectorMar 04Option Exercise8.465,00042,30018,792Mar 06 08:01 PM
Wigzell Hans Lennart RudolfDirectorMar 04Sale116.895,000584,45013,792Mar 06 08:01 PM